Ert Pompe denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny ERT for Pompe Disease as "Duplicate Therapy"

A "duplicate therapy" denial from a Blue Cross Blue Shield plan typically means the insurer's system flagged that a claim for ERT was submitted while another similar claim — or an active prior authorization — was already on file. This can occur when a patient transitions between ERT products (for example, due to a formulary change, a switch between originator and late-entry products, or a change in infusion provider), when a prior authorization was renewed and a new claim overlapped, or due to a billing error at the pharmacy or infusion center.

This type of denial is often administrative rather than clinical in nature, and it is among the more resolvable on appeal.

## Why This Denial Is Appealable

If only one ERT product is actually being administered and there is no true duplication of treatment, this denial rests on a factual error. BCBS is required to explain what the "duplicate" therapy is, and you are entitled to respond with documentation showing no actual overlap.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits (EOB), typically 180 days. For standard appeals, BCBS must respond within 30 days; expedited appeals (appropriate when delay would harm health) within 72 hours.
• External review (ACA §2719): If the internal appeal is denied, request independent external review through your state's designated process. The IRO will assess whether the duplication finding is factually supported.
• ERISA §503 (employer-sponsored plans): Request the complete claims file, including the specific claim or authorization that the insurer identifies as the duplicate.

The external-review window is typically four months from the date of final internal denial.

## Documentation to Gather

• Infusion or dispensing records: Pharmacy or infusion center records showing the exact dates, quantities, and product administered — confirming that only one ERT product was received during the disputed period.
• Prior authorization history: Pull the current and any prior PA numbers for ERT. Confirm there is no active, overlapping authorization for a different product.
• Prescriber clarification letter: A letter from the treating physician confirming that only a single ERT product is prescribed and that no duplicate regimen exists.
• Transition documentation (if applicable): If the patient switched from one ERT product to another, document the specific stop date of the prior product and the start date of the new one, with a gap or a clear transition note.
• Denial details: Request from BCBS the specific claim number and product they identify as the "duplicate" so your response directly addresses it.

## Criteria-Mapping Structure

Obtain the BCBS duplicate-therapy policy language. Build your response around each factual element the plan relied on:

| Insurer's Basis for Denial | Your Corrective Documentation | |---|---| | Identified "duplicate" claim or PA | [Specific claim/PA number + explanation of why it does not represent ongoing dual therapy] | | Overlapping dates of service | [Dispensing/infusion records showing actual administration dates] | | Same therapeutic class | [Prescriber letter confirming single-product regimen] |

Attach the relevant records as exhibits and number them so the reviewer can cross-reference each point easily. Duplicate-therapy denials resolved through a factual record correction typically do not require external review.